The purpose of this call is to support the provision and development of educational content for healthcare professionals on the implementation of personalised medicine.
The objective of this Call is to provide subgrant funding to support the provision and development of educational content aimed at healthcare professionals (HCPs) in the implementation of personalised medicine (PM). The gaps in the PM knowledge and skills among HCPs have been identified as one key barrier to the implementation of PM. This initiative will enhance the capacity of HCPs to integrate PM into their daily practice, ensuring they are equipped with the necessary knowledge, skills, and competencies. The scope of this Call includes general and specialised education on PM and its implementation in clinical practice, interdisciplinary collaboration between HCPs, as well as effective communication of HCPs with patients. The courses will be designed and implemented collaboratively between selected consortia and EP PerMed.
The purpose of the Call is to fund high quality content that will feed into online modules/ courses, that will be collaboratively developed with the Digital Learning Team supporting EP PerMed. All modules/ courses will be hosted and disseminated through the EP PerMed website and the eLearning platform designated by EP PerMed.
Date | Event |
---|---|
4 June 2025 | Opening of the Call for Proposals submission |
16 June 2025 | Opening of application platform |
18 June 2025 at 12:00 CEST | Call information webinar |
16 June – 09 September 2025 | Online matchmaking period |
2 September 2025 at 12:00 CEST | Q&A online session |
9 September 2025 at 16:00 CEST | Deadline for proposals submissions |
10 – 16 September 2025 | Eligibility check |
17 September 2025 | Notification of eligibility check outcome and invite to online pitches |
6 – 10 October 2025 | Online pitching sessions |
29 October 2025 | Final Results notification |
Minimum 3 partners from 3 different EU/Associated countries, with no more than 2 partners per national funder.
Include academia, clinical/public health, and industry or non-profits to reflect the call's cross-sector ambition
Optional: add patient/citizen organizations as extra partners .
All proposals must align with the Strategic Research & Innovation Agenda (SRIA) for personalised medicine, covering areas like patient stratification, omics, biomarkers, or PM implementation
For JTC2025 ("PGxPM2025"), the focus is specifically on pharmacogenomics—from discovery to validation to dosage and response optimization using omics .
Fast Track calls emphasize rigorous validation studies to bridge innovation-to-market gaps
Venture Builder programs prioritize team composition (scientific, clinical, business), innovativeness, feasibility, sustainability, and patient impact
Use 2-step submissions: ensure a competitive pre-proposal, then a strong full proposal (with rebuttal phase for JTC)
Define measurable milestones, sustainable usage, and a clear path from discovery to implementation.
Include industry partners, regulators/HTA representatives, and patient/citizen organizations to support translational relevance
Aim for interdisciplinary integration—mix biological/clinical and socio-economic or implementation sciences
Strictly follow application processes and use mandated templates, language, partner composition rules, and deadlines (common timeline: pre-proposal Feb 2025; full proposal Jun 2025) .
Dual submissions may be required (Call Secretariat and national funder portals, e.g., FWF)
🔑 Summary Table
Predictor | Required Action |
---|---|
Transnational multi-sector consortium | 3+ partners, academia/clinic/industry, patient orgs optional |
Alignment with SRIA & topic standard | Address personalised medicine via biomarkers/omics or pharmacogenomics |
Validation & feasibility focus | Define concrete milestones and real-world measures |
Balanced team strength | Include scientific, clinical, business expertise |
Stakeholder integration | Partner with regulators, HTA, patients |
Compliance with structure & timeline | Pre-proposal > full proposal > rebuttal; use correct portals and templates |
🛠 Pro Tips
Start your consortium early—meet geographic and sector requirements efficiently.
Map your aims to the SRIA, especially pharmacogenomics for JTC2025.
Highlight validation strategy: clear outcomes, data plans, proof-of-concept in real-world settings.
Draft a compelling team profile for Venture: describe founder skills, coachability, feasibility.
Include patient/HTA/regulator voices to strengthen translational readiness.
Use all guidance documents—call text, templates, national rules—during planning.
For an application to proceed to evaluation, it must meet all the below eligibility criteria. Each application will be reviewed for this eligibility criteria by EP PerMed Partners.
Sponsor Institute/Organizations: European Partnership for Personalised Medicine
Sponsor Type: Corporate/Non-Profit
Address: Heinrich-Konen-Straße 5, 53227 Bonn, Germany
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Sep 09, 2025
Sep 09, 2025
$58,736
Affiliation: European Partnership for Personalised Medicine
Address: Heinrich-Konen-Straße 5, 53227 Bonn, Germany
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.